BridgeBio Oncology slides as it tightens the scope of its KRAS program

BridgeBio Oncology Therapeutics' share price {$BBOT} plummeted by about 24% at market close Wednesday on the back of plans that it is scaling back its pipeline to focus on developing its lead KRAS inhibitor for ...